Opthea Limited Sponsored ADR (OPT) has released an update.
Opthea Limited, a biopharmaceutical firm focusing on treatments for retinal diseases like wet AMD, will participate in the UBS Virtual Ophthalmology Day 2024, where its management will engage in a fireside chat and one-on-one meetings with investors. The event will be held on October 2, 2024, and will be webcasted, with Opthea’s CEO Frederic Guerard presenting. The company is currently conducting two pivotal Phase 3 trials for their leading product candidate, sozinibercept, aimed at improving treatment efficacy for retinal diseases when used with existing therapies.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.
